102 related articles for article (PubMed ID: 7527638)
1. The use of plasma levels for FK 506 dosing in liver-grafted patients.
Winkler M; Ringe B; Rodeck B; Melter M; Stoll K; Baumann J; Wonigeit K; Pichlmayr R
Transpl Int; 1994 Aug; 7(5):329-33. PubMed ID: 7527638
[TBL] [Abstract][Full Text] [Related]
2. FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation.
Woodle ES; Bruce DS; Josephson M; Newell KA; Piper JB; Millis JM; Cronin D; Whitman G; Ruebe M; Thistlethwaite JR
Clin Transplant; 1996 Aug; 10(4):323-32. PubMed ID: 8884103
[TBL] [Abstract][Full Text] [Related]
3. Plasma vs whole blood for therapeutic drug monitoring of patients receiving FK 506 for immunosuppression.
Winkler M; Ringe B; Baumann J; Loss M; Wonigeit K; Pichlmayr R
Clin Chem; 1994 Dec; 40(12):2247-53. PubMed ID: 7527306
[TBL] [Abstract][Full Text] [Related]
4. Conversion from cyclosporin to FK 506 after liver transplantation.
Winkler M; Ringe B; Jost U; Melter M; Rodeck B; Buhr T; Brinkmann C; Pichlmayr R
Transpl Int; 1993; 6(6):319-24. PubMed ID: 7507677
[TBL] [Abstract][Full Text] [Related]
5. Optimal FK 506 dosage in patients under primary immunosuppression following liver transplantation.
Winkler M; Pichlmayr R; Neuhaus P; McMaster P; Calne R; Otto G; Williams R; Bismuth H; Groth C
Transpl Int; 1994; 7 Suppl 1():S58-63. PubMed ID: 11271312
[TBL] [Abstract][Full Text] [Related]
6. FK 506 in liver transplantation: correlation of whole blood levels with efficacy and toxicity. The US Multicenter FK 506 Dose Optimization.
Schwartz M; Holst B; Facklam D; Buell D
Transplant Proc; 1995 Feb; 27(1):1107. PubMed ID: 7533355
[No Abstract] [Full Text] [Related]
7. Rejection episodes after liver transplantation during primary immunosuppression with FK506 or a cyclosporine-based regimen: a controlled, prospective, randomized trial.
Jonas S; Kling N; Bechstein WO; Blumhardt G; Lohmann R; Lobeck H; Neuhaus P
Clin Transplant; 1995 Oct; 9(5):406-14. PubMed ID: 8541635
[TBL] [Abstract][Full Text] [Related]
8. FK 506 rescue therapy for resistant rejection episodes in liver transplant recipients.
D'Alessandro AM; Kalayoglu M; Pirsch JD; Corwith C; Knechtle SJ; Reed A; Belzer FO
Transplant Proc; 1991 Dec; 23(6):2987-8. PubMed ID: 1721335
[No Abstract] [Full Text] [Related]
9. Whole blood and plasma levels of FK 506 after liver transplantation: correlation with toxicity.
Bäckman L; Nicar M; Levy M; Distant D; Eisenstein C; Renard T; Goldstein R; Husberg B; Gonwa T; Klintmalm G
Transplant Proc; 1994 Jun; 26(3):1804. PubMed ID: 7518160
[No Abstract] [Full Text] [Related]
10. Use of Prograf (FK 506) as rescue therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group.
Klintmalm GB; Goldstein R; Gonwa T; Wiesner RH; Krom RA; Shaw BW; Stratta R; Ascher NL; Roberts JW; Lake J
Transplant Proc; 1993 Feb; 25(1 Pt 1):679-88. PubMed ID: 7679840
[TBL] [Abstract][Full Text] [Related]
11. Plasma level-guided low-dose FK 506 therapy in patients with early liver dysfunction after liver transplantation.
Winkler M; Ringe B; Jost U; Gubernatis G; Pichlmayr R
Transplant Proc; 1993 Aug; 25(4):2688-90. PubMed ID: 7689277
[No Abstract] [Full Text] [Related]
12. The treatment of intractable rejection with tacrolimus (FK506) in pediatric liver transplant recipients.
McDiarmid SV; Wallace P; Vargas J; Ament ME; Busuttil RW
J Pediatr Gastroenterol Nutr; 1995 Apr; 20(3):291-9. PubMed ID: 7541834
[TBL] [Abstract][Full Text] [Related]
13. Strategy of FK 506 therapy in liver transplant patients: effect of graft function.
Abu-Elmagd KM; Fung JJ; Alessiani M; Jain A; Takaya S; Venkataramanan R; Warty VS; Shannon W; Todo S; Tzakis A
Transplant Proc; 1991 Dec; 23(6):2771-4. PubMed ID: 1721272
[No Abstract] [Full Text] [Related]
14. Four-hour versus 24-hour intravenous infusion of FK 506 in liver transplantation.
Abu-Elmagd KM; Fung J; Draviam R; Shannon W; Jain A; Alessiani M; Takaya S; Venkataramanan R; Warty VS; Tzakis A
Transplant Proc; 1991 Dec; 23(6):2767-70. PubMed ID: 1721271
[No Abstract] [Full Text] [Related]
15. Complete reversal of FK 506 induced diabetes in a liver transplant recipient by change of immunosuppression to cyclosporine A.
Kanzler S; Lohse AW; Schirmacher P; Hermann E; Otto G; Meyer zum Büschenfelde KH
Z Gastroenterol; 1996 Feb; 34(2):128-31. PubMed ID: 8659188
[TBL] [Abstract][Full Text] [Related]
16. Tacrolimus-induced cholestatic syndrome following pediatric liver transplantation and steroid-resistant graft rejection.
Ganschow R; Albani J; Grabhorn E; Richter A; Burdelski M
Pediatr Transplant; 2006 Mar; 10(2):220-4. PubMed ID: 16573611
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors for successful conversion from cyclosporine to FK 506-based immunosuppressive therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group.
Klintmalm GB; Goldstein R; Gonwa T; Wiesner RH; Krom RA; Shaw BW; Stratta R; Ascher NL; Roberts JW; Lake J
Transplant Proc; 1993 Feb; 25(1 Pt 1):641-3. PubMed ID: 7679828
[No Abstract] [Full Text] [Related]
18. Four-year follow-up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation.
Fisher RA; Stone JJ; Wolfe LG; Rodgers CM; Anderson ML; Sterling RK; Shiffman ML; Luketic VA; Contos MJ; Mills AS; Ferreira-Gonzalez A; Posner MP
Clin Transplant; 2004 Aug; 18(4):463-72. PubMed ID: 15233827
[TBL] [Abstract][Full Text] [Related]
19. FK 506 rescue therapy for hepatic allograft rejection: experience with an aggressive approach.
Woodle ES; Perdrizet GA; So SK; White HM; Marsh JW
Clin Transplant; 1995 Feb; 9(1):45-52. PubMed ID: 7537988
[TBL] [Abstract][Full Text] [Related]
20. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation.
Kershner RP; Fitzsimmons WE
Transplantation; 1996 Oct; 62(7):920-6. PubMed ID: 8878385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
